Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 525 of 2873 entries
View as:

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Phase: N/A Priority: Normal
NCT ID: NCT01815333 Org: User:
Start: 07/31/13 End: 07/25/19 Due: 07/25/20

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03132454 Org: User:
Start: 07/25/17 End: 12/31/27 Due: 12/31/28

Chemotherapy-Induced Peripheral Neuropathy Survey

Phase: N/A Priority: Normal
NCT ID: NCT01016028 Org: User:
Start: 11/30/09 End: 02/28/13 Due: 02/28/14

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04789668 Org: User:
Start: 01/15/21 End: 12/08/23 Due: 12/08/24

Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02295956 Org: User:
Start: 02/02/15 End: 06/06/19 Due: 06/06/20

Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00508170 Org: User:
Start: 03/31/06 End: 01/31/10 Due: 01/31/11

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase: N/A Priority: Normal
NCT ID: NCT01183663 Org: User:
Start: 08/31/10 End: 05/31/16 Due: 05/31/17

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03177460 Org: User:
Start: 06/07/17 End: 01/30/24 Due: 01/30/25

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Phase: N/A Priority: Normal
NCT ID: NCT04062266 Org: User:
Start: 09/13/19 End: 10/31/30 Due: 10/31/31

LY2275796 in Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00903708 Org: User:
Start: 09/30/06 End: 06/30/10 Due: 06/30/11

A Feasibility Study of Prophylactic White Blood Cell Transfusions

Phase: N/A Priority: Normal
NCT ID: NCT01932710 Org: User:
Start: 09/20/13 End: 11/30/16 Due: 11/30/17

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Phase: N/A Priority: Normal
NCT ID: NCT00867477 Org: User:
Start: 03/31/09 End: 08/31/14 Due: 08/31/15

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Phase: N/A Priority: Normal
NCT ID: NCT06377527 Org: User:
Start: 07/10/24 End: 12/28/37 Due: 12/28/38

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

Phase: N/A Priority: Normal
NCT ID: NCT04189783 Org: User:
Start: 06/08/20 End: 12/31/26 Due: 12/31/27

Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00506311 Org: User:
Start: 02/28/03 End: 03/31/08 Due: 03/31/09

Quantitative Analysis of Outcomes in Breast Reconstruction

Phase: N/A Priority: Normal
NCT ID: NCT00677430 Org: User:
Start: 05/31/08 End: 04/09/21 Due: 04/09/22

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02131584 Org: User:
Start: 09/02/14 End: 09/30/26 Due: 09/30/27

Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02107105 Org: User:
Start: 05/16/14 End: 05/31/25 Due: 05/31/26

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04128748 Org: User:
Start: 05/27/20 End: 12/31/25 Due: 12/31/26

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Phase: N/A Priority: Normal
NCT ID: NCT00413166 Org: User:
Start: 12/31/06 End: 02/29/16 Due: 02/28/17

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Paranteral Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Randomized Controlled Study

Phase: N/A Priority: Normal
NCT ID: NCT06004063 Org: User:
Start: 08/04/23 End: 12/31/29 Due: 12/31/30

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06548412 Org: User:
Start: 01/22/25 End: 05/01/29 Due: 05/01/30

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03819296 Org: User:
Start: 02/21/21 End: 10/31/25 Due: 10/31/26

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06235801 Org: User:
Start: 05/22/24 End: 10/01/29 Due: 10/01/30

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT03583710 Org: User:
Start: 08/20/18 End: 01/01/29 Due: 01/01/30